ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Durvalumab Induces Sustained Survival Benefit After Concurrent Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Jean-Louis PujolPubMed ↗Publisher ↗

No numbers read from the abstract.